Simultaneous Inhibition of BCR-ABL1 Tyrosine Kinase and PAK1/2 Serine/Threonine Kinase Exerts Synergistic Effect against Chronic Myeloid Leukemia Cells
Tyrosine kinase inhibitors (TKIs) revolutionized the treatment of chronic myeloid leukemia in the chronic phase (CML-CP). However, it is unlikely that they can completely “cure” the disease. This might be because some subpopulations of CML-CP cells such as stem and progenitor cel...
Main Authors: | Sylwia Flis, Ewelina Bratek, Tomasz Chojnacki, Marlena Piskorek, Tomasz Skorski |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2019-10-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/11/10/1544 |
Similar Items
-
The Use of Nanomedicine to Target Signaling by the PAK Kinases for Disease Treatment
by: Yiling Wang, et al.
Published: (2021-12-01) -
2nd EURO-PAK International Conference on Sports Sciences & Physical Education
by: Saša Pišot
Published: (2020-10-01) -
A combination of STI571 and BCR-ABL1 siRNA with overexpressed p15INK4B induced enhanced proliferation inhibition and apoptosis in chronic myeloid leukemia
by: D.Y. Xia, et al.
Published: (2014-12-01) -
A Study on BCR-ABL Kinase Domain Mutations in Chronic Myeloid Leukemia from Western India
by: Pankaj Gadhia, et al.
Published: (2021-10-01) -
Imatinib Mesylate (STI 571) – A New Oral Target Therapy For Chronic Myelogenous Leukemia (CML)
by: Ladislav Chrobák, et al.
Published: (2003-01-01)